← Leaderboards
Thomas John Kremen
Va Greater Los Angeles Healthcare System
$0
Attributed
$0
Total exposure
1
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $0 · FY2020–24$1$1$1$0$0
'20
'21
'22
'23
'24
Funding mix
By agency
VA$0 · 1
By mechanism
IK2$0 · 1
Top collaborators
No co-investigators on record.
Most similar at Va Greater Los Angeles Healthcare System
Same institution · by research overlap
Others in their field
Other Emerging Leaders on “Clinical Efficacy”
- Beth Baseler · Leidos Biomedical Research, Inc.$158,728,629
- Kimberly Smith · Ppd Development Lp$122,008,792
- Yunda Huang · Fred Hutchinson Cancer Center$73,875,286
- Susan Abushakra · Alzheon, Inc.$50,765,244
- Julie Ake · National Institute Of Allergy And Infectious Diseases$50,742,120
- Timothy Fouts · Advanced Bioscience Laboratories, Inc.$41,541,738
Research focus
Clinical EfficacyAffect3d PrintCellular MorphologyAnterior Cruciate Ligament ReconstructionAnterior Cruciate Ligament RuptureAnimal ModelAwardAnterior Cruciate Ligament InjuryBiologicalBiologyBiomechanicsBiomimeticsBisphosphonateArchitectureBoneBone CellBone HealingBackCareerCareer DevelopmentCartilageCathepsin KClinical Trials
Grant awards (5)
Enhanced Soft Tissue-to-Bone Healing via Treatment with Novel Growth Factor NELL-1: Targeted Delivery and Biomimetic Scaffolds$0
IK2 · FY2024 · VA · contact PI
Enhanced Soft Tissue-to-Bone Healing via Treatment with Novel Growth Factor NELL-1: Targeted Delivery and Biomimetic Scaffolds$0
IK2 · FY2023 · VA · contact PI
Enhanced Soft Tissue-to-Bone Healing via Treatment with Novel Growth Factor NELL-1: Targeted Delivery and Biomimetic Scaffolds$0
IK2 · FY2022 · VA · contact PI
Enhanced Soft Tissue-to-Bone Healing via Treatment with Novel Growth Factor NELL-1: Targeted Delivery and Biomimetic Scaffolds$0
IK2 · FY2021 · VA · contact PI
Enhanced Soft Tissue-to-Bone Healing via Treatment with Novel Growth Factor NELL-1: Targeted Delivery and Biomimetic Scaffolds$0
IK2 · FY2020 · VA · contact PI